A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2011
10/11/2011	CA2455768C Antitumoral analogs of et-736
10/11/2011	CA2453978C Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors
10/11/2011	CA2442993C Nucleic acid and corresponding protein entitled 158p3d2 useful in treatment and detection of cancer
10/11/2011	CA2438116C Amphoteric liposomes and the use thereof
10/11/2011	CA2438094C Increased recovery of active proteins
10/11/2011	CA2424734C Nanoparticles comprising a metallic or semiconductor core which is covalently bound to a plurality of carbohydrate ligands
10/11/2011	CA2393410C Phosphonate compounds
10/11/2011	CA2378584C New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy
10/11/2011	CA2362098C Human polyclonal antibodies from genetically engineered animals
10/11/2011	CA2341356C Poxvirus with targeted infection specificity
10/11/2011	CA2336743C Antigenic peptides derived from telomerase
10/11/2011	CA2157932C Production of human papillomavirus capsid protein and virus-like particles
10/06/2011	WO2011123858A2 Ccn3 peptides and analogs thereof for therapeutic use
10/06/2011	WO2011123819A2 Epha3 antibodies for the treatment of multiple myeloma
10/06/2011	WO2011123691A1 Perifosine and capecitabine as a combined treatment for cancer
10/06/2011	WO2011123683A2 Protease activated cytokines
10/06/2011	WO2011123678A2 Substituted benzo-pyrido-triazolo-diazepine compounds
10/06/2011	WO2011123524A2 Macrolide inhibitors of mtor
10/06/2011	WO2011123493A1 Substituted pyrrolotriazines as protein kinase inhibitors
10/06/2011	WO2011123427A2 Treatment of cancer by inhibiting activity or expression of late sv-40 factor
10/06/2011	WO2011123395A1 Methods of treating cancer
10/06/2011	WO2011123393A1 Methods of enhancing drug delivery and effectiveness of therapeutic agents
10/06/2011	WO2011123381A1 Antibodies against csf-1r
10/06/2011	WO2011123027A1 Improved treatment of renal cell carcinoma
10/06/2011	WO2011122916A2 Composition for increasing trail sensitivity, containing an inhibitor for inhibiting the expression or activity of tip41 which is a trail sensitizer target gene
10/06/2011	WO2011122619A1 Phenylalanine derivative salt crystal
10/06/2011	WO2011122611A1 Cancer vaccine
10/06/2011	WO2011121629A1 Indolic derivatives and use thereof in medical field
10/06/2011	WO2011121453A2 Methods and compositions for treating or ameliorating cancer using gemcitabine-5'-elaidate
10/06/2011	WO2011121434A1 NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NMPRTase) INHIBITOR FOR GLIOMA THERAPY
10/06/2011	WO2011121366A1 Pyrazole p38 map kinase inhibitors
10/06/2011	WO2011121317A1 Imidazo [2,1-b] [1,3,4] thiadiazoles as protein or lipid kinase inhibitors
10/06/2011	WO2011121223A1 6-(alkyl- or cycloalkyl-triazolopyridazine-sulfanyl) benzothiazole derivatives: preparation, application as medicaments and use as met inhibitors
10/06/2011	WO2011121068A1 Amino derivatives of cyclohex-2-enone, their preparation and use as antioxidants
10/06/2011	WO2011121055A1 Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
10/06/2011	WO2011120922A1 Use of novel pan-cdk inhibitors for treating tumors
10/06/2011	WO2011120911A1 Pkc inhibitors for the treatment of b-cell lymphoma having chronic active b-cell-receptor signalling
10/06/2011	WO2011120902A1 Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and tumor initiating cells
10/06/2011	WO2011120886A1 A process for the preparation of (-)-englerin a, and analogues and intermediates thereof
10/06/2011	WO2011120870A1 Egfr inhibitor and antiviral agent for simultaneous, separate or sequential use in the treatment and/or prevention and/or palliation of cancer
10/06/2011	WO2011120339A1 Microemulsion formulation containing arctigenin
10/06/2011	WO2011120332A1 Double-stranded rna molecules with stability in mammalian body fluid, preparation and application thereof
10/06/2011	WO2011120327A1 Anti-tumor medicament of structure of diarylurea or thiourea kind based on indazole or aza-indazole
10/06/2011	WO2011120314A1 Biphenyl compounds with antitumor activity and their preparation method
10/06/2011	WO2011120313A1 Biphenyl compounds with antitumor activity and their preparation method
10/06/2011	WO2011120303A1 Gambogic acid derivatives, preparative methods and uses thereof
10/06/2011	WO2011120135A1 Antibodies with enhanced or suppressed effector function
10/06/2011	WO2011120134A1 Antibodies with enhanced or suppressed effector function
10/06/2011	WO2011120099A1 Diagnostic and prognostic methods for cancer
10/06/2011	WO2011120082A1 A method of modulating protein 14-3-3 functionality by facilitating or inhibiting phosphorylation
10/06/2011	WO2011094806A8 Diagnostic and prognostic assay for breast cancer
10/06/2011	WO2011089234A3 Aqueous solution comprising 3 - quinuclidinones for the treatment hyperproliferative, autoimmune and heart disease
10/06/2011	WO2011083090A3 Methods for treating breast cancer
10/06/2011	WO2011081294A3 Recombinant adenovirus having anti-angiogenesis activity
10/06/2011	WO2011072138A9 Therapeutic use of protein-polymer conjugates
10/06/2011	WO2011071632A3 Modified insm1-promoter for neuroendocrine tumor therapy and diagnostics
10/06/2011	WO2011069141A3 Interferon therapies in combination with blockade of stat3 activation
10/06/2011	WO2011066260A3 Formulations comprising aminosterols
10/06/2011	WO2011060268A3 Diagnosis and treatment of cancer using histone deacetylase inhibitors and radiolabeled metaiodobenzylguanidine
10/06/2011	WO2011059926A9 Methods and materials for treating renal cell carcinoma
10/06/2011	WO2011059763A3 Dimeric smac mimetics
10/06/2011	WO2011058508A3 Compositions for the treatment of chemoresistant leukaemia and/or of potentially chemoresistant leukaemia
10/06/2011	WO2011054359A3 Method for early detection of cancer using o - glycosylated mucin peptides or corresponding monoclonal antibodies
10/06/2011	WO2011053660A3 Novel therapeutic rna interference technology targeted to the pdx-1 oncogene in pdx-1 expressing neuroendocrine tumors
10/06/2011	WO2011050357A3 Protein arginine deiminase inhibitors as novel therapeutics for rheumatoid arthritis and cancer
10/06/2011	WO2011046382A3 Nrf2 inhibitors and use thereof
10/06/2011	WO2011044533A3 Coating system and method for drug elution management
10/06/2011	WO2011041319A8 Specific binding proteins and uses thereof
10/06/2011	WO2011035143A4 Methods and compositions for inhibiting rho-mediated diseases and conditions
10/06/2011	WO2011034775A3 Methods for treating brain tumors
10/06/2011	WO2011034583A3 Inhibition of endosomal toll-like receptor activation
10/06/2011	WO2010104406A8 Prodrug forms of kinase inhibitors and their use in therapy
10/06/2011	WO2010102363A8 Auxotrophic, recombinant bcg strain pasteur and use thereof for combating human infections caused by parasites
10/06/2011	US20110247087 Regulation of endogenous gene expression in cells using zinc finger proteins
10/06/2011	US20110245339 Prodrugs of short-chain fatty acids and treatment methods
10/06/2011	US20110245337 Method for enhancing the dna repair process, treating disorders associated with the dna repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering purified quinic acid and/or carboxy alkyl ester
10/06/2011	US20110245335 New inhibitors for treating diseases associated with an excess transport of hyaluronan
10/06/2011	US20110245332 Injectable formulations of taxanes for cad treatment
10/06/2011	US20110245330 P185neu-encoding dna and therapeutical uses thereof
10/06/2011	US20110245327 Oligonucleotide Analogues
10/06/2011	US20110245325 Pharmaceutical composition for treatment of cancer and asthma
10/06/2011	US20110245323 RIG-Like Helicase Innate Immunity Inhibits VEGF-Induced Tissue Responses
10/06/2011	US20110245318 Rna sequence-specific mediators of rna interference
10/06/2011	US20110245315 Indolyl or indolinyl hydroxamate compounds
10/06/2011	US20110245309 N-methylpurine dna glycosylase and polymerase beta as biomarkers for alkylator chemotherapy potentiation
10/06/2011	US20110245304 Ribonucleotide reductase inhibitors and methods of use
10/06/2011	US20110245303 Heteroalkyl biphenyl antagonists of prostaglandin d2 receptors
10/06/2011	US20110245295 Bioactive pre-tubulysins and use thereof
10/06/2011	US20110245289 Novel substituted imidazoquinolines
10/06/2011	US20110245282 Compounds
10/06/2011	US20110245279 Predictive marker for egfr inhibitor treatment
10/06/2011	US20110245262 Compounds for treating proliferative disorders
10/06/2011	US20110245260 Analogs of dehydrophenylahistins and their therapeutic use
10/06/2011	US20110245257 Heterocyclic compounds and their uses
10/06/2011	US20110245256 Use of a pkc inhibitor
10/06/2011	US20110245252 Pyrrolotriazine kinase inhibitors
10/06/2011	US20110245248 Isoquinoline derivatives
10/06/2011	US20110245246 Quinazoline Derivatives Useful as Anti-Tumor Medicament
10/06/2011	US20110245245 Methods of treatment comprising the administration of heteroaryl compounds
10/06/2011	US20110245238 Novel Soluble 1,4 Benzodiazepine Compounds and Stable Salts Thereof

1 ... 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 ... 2211